MYDA Advisors’s VistaGen Therapeutics VTGN Stock Holding History

MYDA Advisors’s Portfolio VTGN Stock Details VTGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-50,000	Closed	-$262K	–	128
2023 Q3	$262K	Buy	+50,000	New	+$222K	0.08%	89

Other funds holding VTGN

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Stempoint Capital New York $522M AUM 281.95% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Citadel Advisors

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

MYDA Advisors's VTGN Position: Q4 2023 in Review

MYDA Advisors sold out of VistaGen Therapeutics (VTGN) in Q4 2023, closing a stake of 50,000 shares — an estimated $262K sold.

MYDA Advisors first reported a position in VTGN in Q3 2023 and held it in 1 quarter. The position peaked at $262K in Q3 2023. 46 funds tracked by Wall St. Rank hold VTGN as of Q4 2023.

MYDA Advisors reported no remaining VistaGen Therapeutics position as of Q4 2023 after selling out during the quarter.
MYDA Advisors sold 50,000 VistaGen Therapeutics shares in Q4 2023, an estimated $262K.
MYDA Advisors first reported a position in VistaGen Therapeutics in Q3 2023 and held it in 1 quarter.
MYDA Advisors's VistaGen Therapeutics position peaked at $262K in Q3 2023.
46 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q4 2023.

Based on MYDA Advisors's 13F filing for Q4 2023, filed 13 Feb 2024.